GGHC
AGIO icon

Gilder Gagnon Howe & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-367,726
Closed -$23.9M – 235
2015
Q4 		$23.9M Sell
367,726
-43,927
-11% -$2.88M 0.38% 61
2015
Q3 		$29.1M Sell
411,653
-3,807
-0.9% -$372K 0.46% 60
2015
Q2 		$46.2M Buy
415,460
+343,378
+476% +$37M 0.61% 47
2015
Q1 		$6.8M Sell
72,082
-31,234
-30% -$3.5M 0.09% 123
2014
Q4 		$11.6M Buy
103,316
+93,293
+931% +$8.33M 0.17% 93
2014
Q3 		$615K Buy
+10,023
New +$432K 0.01% 222

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Gilder Gagnon Howe & Co's AGIO Position: Q1 2016 in Review

Gilder Gagnon Howe & Co sold out of Agios Pharmaceuticals (AGIO) in Q1 2016, closing a stake of 367,726 shares — an estimated $23.9M sold.

Gilder Gagnon Howe & Co first reported a position in AGIO in Q3 2014 and held it in 6 quarters. The position peaked at $46.2M in Q2 2015. 157 funds tracked by Wall St. Rank hold AGIO as of Q1 2016.

  • Gilder Gagnon Howe & Co reported no remaining Agios Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 367,726 Agios Pharmaceuticals shares in Q1 2016, an estimated $23.9M.
  • Gilder Gagnon Howe & Co first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • Gilder Gagnon Howe & Co's Agios Pharmaceuticals position peaked at $46.2M in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2016, filed 3 May 2016.